MedTrace Logo

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

NCT01460160 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2021-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia

Conditions

  • Leukemia, Pediatric

Interventions

DRUG

Dasatinib

Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity

Sponsors & Collaborators

  • Children's Oncology Group

    collaborator NETWORK

  • EsPhALL

    collaborator OTHER

  • Bristol-Myers Squibb

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-13
Primary Completion
2017-05-28
Completion
2021-06-01

Countries

  • United States
  • Australia
  • Canada
  • Italy
  • Puerto Rico
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460160 on ClinicalTrials.gov